Pemphigus Vulgaris clinical trials

Explore recruiting pemphigus vulgaris clinical trials.

Recruiting pemphigus vulgaris studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pemphigus Vulgaris trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corticosteroids) in pemphigus - (RITUX 4)

France

Therapeutic use (Phase IV) EU CTIS Study details

Pemphigus Vulgaris trials by city

Pemphigus Vulgaris in Toronto Pemphigus Vulgaris in Vancouver Pemphigus Vulgaris in Montreal Pemphigus Vulgaris in Calgary Pemphigus Vulgaris in Edmonton Pemphigus Vulgaris in Ottawa Pemphigus Vulgaris in Winnipeg Pemphigus Vulgaris in Quebec City Pemphigus Vulgaris in Hamilton Pemphigus Vulgaris in Kitchener Pemphigus Vulgaris in London Pemphigus Vulgaris in Halifax Pemphigus Vulgaris in New York Pemphigus Vulgaris in Los Angeles Pemphigus Vulgaris in Chicago Pemphigus Vulgaris in Houston

Pemphigus Vulgaris clinical trials

Recruiting pemphigus vulgaris studies right now

Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris

Also recruiting in Europe

Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial

Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corticosteroids) in pemphigus - (RITUX 4)

Pemphigus Vulgaris trials by city

Other conditions